Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Cirrhosis

  Free Subscription


17.12.2018

3 Gastroenterology
4 Hepatology
5 J Hepatol
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Gastroenterology

  1. MAJEED A, Roberts SK, Kemp W
    RE: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients with Cirrhosis.
    Gastroenterology. 2018 Dec 10. pii: S0016-5085(18)35391.
    PubMed     Text format    

  2. LIDOFSKY SD
    Screening For Hepatocellular Carcinoma In Cirrhosis: Challenges And Unresolved Issues.
    Gastroenterology. 2018 Dec 10. pii: S0016-5085(18)35390.
    PubMed     Text format    

  3. LOOMBA R, Kayali Z, Noureddin M, Ruane P, et al
    GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease.
    Gastroenterology. 2018 Jul 27. pii: S0016-5085(18)34815.
    PubMed     Text format     Abstract available


    Hepatology

  4. RAND EB
    Cirrhotic Cardiomyopathy in children with BA: A new objective parameter to predict morbidity and mortality on the waitlist - and beyond!
    Hepatology. 2018 Dec 12. doi: 10.1002/hep.30419.
    PubMed     Text format     Abstract available

  5. VERMA N, Singh A, Singh V
    Reply.
    Hepatology. 2018;68:388.
    PubMed     Text format    

  6. GULAMHUSEIN AF, Lazaridis KN
    Primary Biliary Cholangitis, DNA and Beyond: The Relative Contribution of Genes.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29783.
    PubMed     Text format    

  7. HERNAEZ R, Kanwal F, El-Serag HB
    Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis.
    Hepatology. 2018;68:7-9.
    PubMed     Text format    


    J Hepatol

  8. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    

  9. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    

  10. STENGEL S, Stallmach A, Richter K, Landrock A, et al
    Serum metabolic signatures in patients with overt hepatic encephalopathy.
    J Hepatol. 2017 Jul 6. pii: S0168-8278(17)32138.
    PubMed     Text format    

  11. GUSTOT T, Agarwal B
    Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation.
    J Hepatol. 2017;67:667-668.
    PubMed     Text format    

  12. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed     Text format    


    PLoS One

  13. HSIEH YC, Lee KC, Wang YW, Yang YY, et al
    Correlation and prognostic accuracy between noninvasive liver fibrosismarkers and portal pressure in cirrhosis: Role of ALBI score.
    PLoS One. 2018;13:e0208903.
    PubMed     Text format     Abstract available

  14. GROTTENTHALER JM, Werner CR, Steurer M, Spengler U, et al
    Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PLoS One. 2018;13:e0197544.
    PubMed     Text format     Abstract available

  15. WANG HW, Shi HN, Cheng J, Xie F, et al
    Real-time shear wave elastography (SWE) assessment of short- and long-term treatment outcome in Budd-Chiari syndrome: A pilot study.
    PLoS One. 2018;13:e0197550.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: